Chinese Journal of Integrative Medicine

, Volume 16, Issue 5, pp 399–405 | Cite as

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial

  • Fu-yong Chu (褚福永)
  • Jie Wang (王 阶)
  • Kui-wu Yao (姚魁武)
  • Zhi-zhong Li (李志忠)
Original Article



Compared with Shengmai Capsule (生脉胶囊, SM), the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule (血府逐瘀胶囊, XFZY) on the symptoms and signs and health-related quality of life (HR-QOL) in the unstable angina (UA) patients with blood-stasis syndrome (BSS) after percutaneous coronary intervention (PCI).


A randomized, double-blinded, double-dummy, and placebo-controlled trial was applied. Ninety patients, diagnosed as UA and BSS after successful PCI, were enrolled and equally randomized into three groups, XFZY group, SM group, and placebo group, and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs (CSS), electrocardiography (ECG), and BSS scores were recorded and compared among groups during and after the treatment. Short-form 36 (SF-36) and Seattle Angina Questionnaire (SAQ) were applied to assess the HR-QOL in each group before and after the treatment. Safety indexes (blood routine and liver and kidney function tests) were also examined at the beginning and after the treatment.


Eighty-six patients completed the whole study. After the treatment, the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%, respectively, which were obviously higher than those in SM (CSS: 53.3%; ECG: 36.7%) and the placebo (CSS: 43.3%; ECG: 30.0%) groups. After one week’s treatment, BSS scores slightly decreased in each group, but no signifificant differences were found among three groups (P>0.05). After four weeks’ treatment, BSS scores in the XFZY group decreased to a lower level compared with SM (P <0.05) and the placebo (P <0.01) groups. After the treatment, the effificacy of XFZY group in improving body pain (BP), general health (GH), vitality (VT), society functioning (SF), role emotional (RE), angina stability (AS), angina frequency (AF), and treatment satisfaction (TS) were better than those in the placebo group (P <0.05,P <0.01). Meanwhile, the dimensions of BP, GH, SF, AS, AF, and TS were better improved than those in the SM group P <0.05). No obvious adverse reaction was found during and after the treatment except one case in the XFZY group reporting of stomach discomfort.


Compared with SM Capsule treatment, a short-term treatment with XFZY Capsule exhibits better effificacy on CSS and BSS scores, and HR-QOL in UA patients with BSS after PCI. However, its long-term effificacy and safety still needs further investigation.


Xuefu Zhuyu Capsule unstable angina percutaneous coronary intervention double-blind double-dummy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000;342:101–114.CrossRefPubMedGoogle Scholar
  2. 2.
    Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911–918.CrossRefPubMedGoogle Scholar
  3. 3.
    Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drugeluting stents: two-year results of the REAL (REgistro AngiopLastiche dell’ Emilia Romagna) multicenter registry. Circulation 2007;115:3181–3188.CrossRefPubMedGoogle Scholar
  4. 4.
    Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247–249.CrossRefPubMedGoogle Scholar
  5. 5.
    van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009;119:828–834.CrossRefPubMedGoogle Scholar
  6. 6.
    Bliley AV, Ferrans CE. Quality of life after coronary angioplasty. Heart Lung 1993; 22:193–199.PubMedGoogle Scholar
  7. 7.
    Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002; 144:826–833.PubMedGoogle Scholar
  8. 8.
    Cronin SN, Freeman LH, Ryan G, Drake DM. Recovery after percutaneous transluminal coronary angioplasty: Assessment after discharge. Critical Care Nurse 2000;20:70–76.PubMedGoogle Scholar
  9. 9.
    Kimble LP, King KB. Perceived side effects and benefits of coronary angioplasty in the early recovery period. Heart Lung 1998;27:308–314.CrossRefPubMedGoogle Scholar
  10. 10.
    Barnason SA, Zimmerman LM, Brey B, Catlin S, Nieveen JL. Patterns of recovery following percutaneous coronary intervention: a pilot study. Appl Nurs Res 2006;19: 31–37.CrossRefPubMedGoogle Scholar
  11. 11.
    Pedersena SS, Denolleta J, Daemen J, van de Sande M, de Jaegere PT, Serruys PW, et al. Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel eluting stents. J Psychosom Res 2007;62: 455–461.CrossRefGoogle Scholar
  12. 12.
    Zheng GL, Wang SH. Clinical effect and mechanism of Xuefu Zhuyu Capsule in treating unstable angina pectoris. Chin J Integr Tradit West Med (Chin) 2009;29:65–68.Google Scholar
  13. 13.
    Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for management of patients with unstable angina and non-ST-segment elevation myocardial infarction summary article. J Am Coll Cardiol 2002; 40:1366–1374.CrossRefPubMedGoogle Scholar
  14. 14.
    Specialty Committee of Activating Blood Circulation and Removing Blood Stasis of Research, Chinese Association of the Integrative Medicine. Diagnostic criteria of bloodstasis syndrome. Chin J Integr Tradit West Med (Chin) 1987;7:cover 2.Google Scholar
  15. 15.
    Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing House; 2002:69–73.Google Scholar
  16. 16.
    Li J, Zhang MZ, Chen BJ, Wang L, Ling XZ, Zhang XW, et al. Effect of Tongguan Capsule (通冠胶囊) on postintervention patients of coronary heart disease with qideficieney and blood stasis syndrome. Chin J Integr Tradit West Med (Chin) 2008;28:32–35.Google Scholar
  17. 17.
    Ware JE. SF-36 health survey mannual and interpretation guide. Boston. MA: The Health Institute; 1993:2–7.Google Scholar
  18. 18.
    Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994; 74:1240–1244.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu J, Hu YM, Yang YB, Wang BH, Xie YN. Health measurement questionnaire SF-36. Chin J Behav Med Sci (Chin) 1999;8:150–153.Google Scholar
  20. 20.
    Yin H, Zhang J, Lin H, Qiao Y, Wang R, Lu H, et al. Effect of traditional Chinese medicine Shu-mai-tang on angiogenesis, arteriogenesis and cardiac function in rats with myocardial ischemia. Phytother Res 2009;23:92–98CrossRefPubMedGoogle Scholar
  21. 21.
    Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Parmar HS, Kar A. Antiperoxidative, antithyroidal, antihyperglycemic and cardioprotective role of Citrus sinensis peel extract in male mice. Phytother Res 2008;22:791–795.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu YZ, Li SQ, Zu XG, Du J, Wang FF. Ginkgo biloba extract improves coronary artery circulation in patients with coronary artery disease: contribution of plasma nitric oxide and endothelin-1. Phytother Res 2008;22:734–739.CrossRefPubMedGoogle Scholar
  24. 24.
    Ling H, Wu L, Li L. Corydalis yanhusuo rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats. Phytother Res 2006;20:448–453.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu YF, Yu HM, Zhang C, Yang RX, Yan FF, Liu Y, et al. Effects of Quyu Xiaoban capsules on Clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris. J Altern Complement Med 2007;13:571–576.CrossRefPubMedGoogle Scholar
  26. 26.
    Tam WY, Chook P, Qiao M, Chan LT, Chan TY, Poon YK, et al. The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients. J Altern Complement Med 2009;15:415–421.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhao J, Huang X, Tang W, Ren P, Xing Z, Tian X, et al. Effect of oriental herbal prescription Guan-Xin-Er-Hao on coronary flow in healthy volunteers and antiapoptosis on myocardial ischemia reperfusion in rat models. Phytother Res 2007;21:926–931.CrossRefPubMedGoogle Scholar
  28. 28.
    Li CY. Progress of the study on blood stasis syndrome and prescriptions and medicinal herbs for activating blood circulation to eliminate stasis. Chin J Integr Tradit West Med (Chin) 1988; 5:317–320.Google Scholar
  29. 29.
    Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005;26:557–563.CrossRefGoogle Scholar
  30. 30.
    Liang ZJ. Research on the scientific basisi of bloodstasis pattern. In: Chen KJ ed. Research on the bloodstasis pattern and activating blood circulation to remove blood-stasis. Shanghai: Shanghai Scientific and Technical Publishers; 1990:368–488.Google Scholar
  31. 31.
    Liu TX, Kong SP, Liao ZY, Lu SK. Assessment study on physical function and the quality of life for CHD patients with SAQ. Chin J Behav Med Sci (Chin) 1997;6:127–129.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Fu-yong Chu (褚福永)
    • 1
  • Jie Wang (王 阶)
    • 1
  • Kui-wu Yao (姚魁武)
    • 1
  • Zhi-zhong Li (李志忠)
    • 2
  1. 1.Department of Cardiology, Guang’anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.Rescue Center of Emergency, Anzhen HospitalChina Capital University of Medical ScienceBeijing 100029China

Personalised recommendations